Claim 50% Off TipRanks Premium and Invest with Confidence
- Unlock hedge-fund level data and powerful investing tools designed to help you make smarter, sharper decisions
- Stay ahead of the market with the latest news and analysis so your portfolio is always positioned for maximum potential
An update from Tryptamine Therapeutics ( (AU:TYP) ) is now available.
Tryptamine Therapeutics announced that Dr. James Gilligan, their Chief Scientific Officer, presented at the Neuropsychiatric Drug Development Summit in Boston, showcasing new data on their lead program, TRP-8803. The presentation highlighted the potential of TRP-8803 to offer a more precise and controllable treatment for neuropsychiatric conditions, which could enhance the company’s standing in the global neuropsychiatric research community. The invitation to this high-profile event underscores the growing recognition of Tryp’s clinical programs and their potential impact on the industry.
More about Tryptamine Therapeutics
Tryptamine Therapeutics Limited is a clinical-stage biotechnology company focused on developing proprietary formulations for administering psilocin in combination with psychotherapy to treat diseases with unmet medical needs. Their lead program, TRP-8803, is an IV-infused psilocin formulation aimed at improving the treatment’s precision and control compared to oral psilocybin.
Average Trading Volume: 1,715,653
Technical Sentiment Signal: Sell
Current Market Cap: A$48.94M
Learn more about TYP stock on TipRanks’ Stock Analysis page.